Alongside anti-cytotoxic T-lymphocyte-asso ciated antigen 4(CTLA-4; ipilimumab), anti-PD-1/ PD-L1 antibodies are currently approved formetastatic melanoma(10). Here, CTLA4 is linked to melanoma.